Why This Matters

A healthcare business model rests on beliefs about who the clinical users are and what they value, who makes purchasing decisions and on what basis, how the product reaches the market, what the reimbursement landscape supports, and whether the economics work for all parties. At the earliest stages, none of these are known. They are assumptions.

The critical discipline is making those assumptions explicit and testing them rigorously. Teams that test assumptions informally tend not to document them, seek confirmation rather than falsification, avoid topics that feel threatening, and interpret anecdotes as validation. The result is a business model built on beliefs that feel solid but have never been examined.

This matters because the most common reason medtech ventures fail is not technical — it is commercial. Analysis of startup post-mortems consistently identifies "no market need" as the leading cause of failure. Not because the need does not exist, but because the team never rigorously tested whether their version of the need, in their target setting, for their target buyer, was real.

Scientific teams are often comfortable with technical hypotheses. Structuring commercial hypotheses with the same rigor is a distinct skill — and one that directly determines whether a promising technology becomes a viable business.

What Makes a Hypothesis Well-Formed

A well-formed business hypothesis is a testable, falsifiable, and operationally defined prediction about how the venture will create, deliver, or capture value. It is phrased as a structured claim about cause and effect, starting with "We believe that..."

Four criteria determine whether a hypothesis is well-formed.

Precise means every key term is operationally defined — interpreted the same way by two independent people. A hypothesis fails this test if it contains unspecified terms like "better," "faster," "easier," "hospitals," or "clinicians" without qualification. If you cannot design a measurement protocol from the statement alone, it is not precise. Upgrade test: can you translate the hypothesis into a data table with defined rows, columns, and units?

Testable means there exists a feasible experiment or observation that could prove the hypothesis wrong. A hypothesis fails this test if it relies on subjective judgments, has no defined metric, or has no clear success criterion. Upgrade test: could a skeptical investor design a way to disprove it?

Discrete means the hypothesis isolates a single causal claim so that results are interpretable. A hypothesis fails this test if it combines multiple stakeholders, bundles multiple benefits, or tests multiple independent variables simultaneously. Upgrade test: if this hypothesis fails, will you know exactly which assumption was invalid?

Actionable means the result of testing it will change what the team does next. A strong hypothesis leads to a pre-committed decision: if yes, we proceed; if no, we pivot X. A weak hypothesis produces interesting information but no strategic decision. Upgrade test: write both decision paths before running the experiment.

Worked Examples

The following three examples are drawn from a single venture: a minimally invasive surgical device for elective colorectal procedures. Each example addresses a different part of the business model, showing how the same rigor applies whether you are hypothesizing about clinical value, institutional purchasing, or reimbursement strategy.

Example 1 — Value Promise (Block 1)

Initial hypothesis: We believe that surgeons will prefer our device because it makes colorectal procedures easier and reduces complications.

Revised hypothesis: We believe that attending colorectal surgeons at 200–400 bed urban academic hospitals performing elective sigmoid resections will achieve a reduction in intraoperative conversion-to-open rate from a baseline of 12% to below 7% within the first ten uses of our device, based on prospective case log review.

Example 2 — Economic Buyers (Block 3)

Initial hypothesis: We believe that hospitals will see our device as cost-effective and support its adoption.

Revised hypothesis: We believe that supply chain directors at 200–400 bed urban academic hospitals will approve budget allocation for our device when total direct variable cost per procedure is demonstrated to be at least 18% below the current standard laparoscopic instrument set, based on published cost data and internal case costing.

Example 3 — Transaction Model (Block 8)

Initial hypothesis: We believe that payers will reimburse our device because it improves patient outcomes.

Revised hypothesis: We believe that US commercial payers covering elective colorectal procedures will issue a positive coverage determination for our device within 24 months of FDA clearance, given published evidence demonstrating a reduction in 30-day readmission rates of at least 25% compared to standard laparoscopic technique, based on a minimum of one peer-reviewed prospective study.

Interdependence

The three examples above are not independent. They are connected. The economic buyer hypothesis assumes a cost advantage that depends on the clinical performance hypothesis. The reimbursement hypothesis assumes a clinical evidence threshold that the same performance data must satisfy. If the Value Promise hypothesis is invalidated — if the conversion-to-open rate does not improve sufficiently — both the economic buyer hypothesis and the reimbursement hypothesis must be revisited immediately, because both were built on the assumption that the clinical claim holds.

This is a property of all business models, not just this one. The H-BMC is a system of interdependent hypotheses. When one is invalidated, the implications ripple across the model. A team that discovers their assumed economic buyer is wrong must immediately revisit every block that assumed that buyer: the Transaction Model, Channels and Customer Relationships, Value Promise, and reimbursement pathway assumptions in the Authorities block.

This is why hypothesis testing must be systematic and documented. An invalidated hypothesis that is not propagated through the model is as dangerous as one that was never tested.